Nuno Mendonça

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 237 citations

Gene Therapies, Clinical Trials, Neurology +2

Sel1L is indispensable for mammalian endoplasmic reticulum-associated degradation, endoplasmic reticulum homeostasis, and survival

Shengyi Sun, Guojun Shi, Xuemei Han et al. · Proceedings of the National Academy of Sciences · 2014 · 208 citations · Full text

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

Tim West, Yan Hu, Philip B. Verghese et al. · PubMed · 2017 · 136 citations

Tau Pathology, Immunology, Pathology +18

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 130 citations · Full text

Clinical Trials, Progressive Supranuclear Palsy, Placebo-controlled Trial +7

Effects of dietary patterns and low protein intake on sarcopenia risk in the very old: The Newcastle 85+ study

Antoneta Granic, Nuno Mendonça, Avan Aihie Sayer et al. · Clinical Nutrition · 2019 · 107 citations · Full text